… In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …

… patients with chronic HF with reduced ejection fraction (HFrEF), evaluating the effect of
dapagliflozin … care, on the risk of worsening HF and cardiovascular death. The trial is registered as …

… with HF may not be related to the left ventricular ejection fraction; therefore, dapagliflozin is
… of dapagliflozin for the management of chronic heart failure. We showed that dapagliflozin …

… dapagliflozin according to the presence or not of AF in the DELIVER (Dapagliflozin Evaluation
to Improve the LIVEs of Patients … patients with heart failure and preserved ejection fraction (…

… -on dapagliflozin treatment for HFpEF and HFmrEF patients. … cost-utility analysis of dapagliflozin
in HFpEF and HFmrEF in … on dapagliflozin treatment for HFpEF and HFmrEF patients to …

… (HHF) and urgent heart failure visit (UHFV) events upon treatment with dapagliflozin plus …
to variations in patient characteristics of left ventricular ejection fraction (LVEF), age, estimated …

… placebo, patients with heart failure with preserved ejection fraction randomized to dapagliflozin
were … Beneficial response to dapagliflozin was consistent across prespecified subgroups. …

… reduced, and preserved ejection fractions. We examined the effects of dapagliflozin on health
status, … The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a …

… patients of interest. Therefore, we have examined these outcomes … patients randomized
in Asia in the DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure…

… Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.  … Resist trial
with dapagliflozin in heart failure and steering committee member for the DAPA-CKD trial with …